Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by Harvard Bioscience, Inc. on May 17, 2018. The filing details the voting results for four specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on the following matters with the results summarized below:
- Election of Directors: Jeffrey A. Duchemin was elected as a Class III Director for a three-year term. He received 25,493,933 votes for, with 446,296 votes withheld.
- Ratification of Auditors: The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified. Votes were 32,587,532 for, 62,423 against, and 9,167 abstained.
- Stock Plan Amendment: Stockholders approved an amendment to the Third Amended and Restated 2000 Stock Option and Incentive Plan to increase authorized shares available for issuance by 3,400,000. Votes were 23,878,151 for, 1,809,410 against, and 252,668 abstained.
- Executive Compensation: The compensation of named executive officers was approved via a non-binding advisory vote. Votes were 25,561,352 for, 360,650 against, and 18,227 abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the historical results of the stockholder vote.
Investor Verification Checklist
- Verify the impact of the 3,400,000 share increase on potential future dilution.
- Confirm the tenure and responsibilities of the newly elected Class III Director, Jeffrey A. Duchemin.
- Review the full proxy statement for details on the specific executive compensation packages approved.
- Check subsequent filings for the official appointment of Grant Thornton LLP for the 2018 fiscal year.